A proof of efficacy study of BIO 11006 in non small cell lung cancer

Trial Profile

A proof of efficacy study of BIO 11006 in non small cell lung cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs BIO-11006 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2017 According to a BioMarck Pharmaceuticals media release, the company received FDA's approval to conduct the trial of BIO-11006 in adults with lung cancer.
    • 20 Sep 2016 According to a BioMarck Pharmaceuticals media release, the company anticipates FDA approval and begin this study in 2017.
    • 20 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top